Research & Literature

The significance and management of thrombocytopenia in antiphospholipid syndrome.

Artim-Esen B, Diz-Küçükkaya R, İnanç M

Current rheumatology reports 2015; (17(3)):14 doi:10.1007/s11926-014-0494-8.

Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases.

Signorelli F, Nogueira F, Domingues V, et al.

Clinical rheumatology 2016; (35(3)):801-5 doi:10.1007/s10067-015-3030-y.

Genetic aspects of the antiphospholipid syndrome: An update.

Sebastiani GD, Iuliano A, Cantarini L, Galeazzi M

Autoimmunity reviews 2016; (15(5)):433-9.

Treatment of catastrophic antiphospholipid syndrome.

Kazzaz NM, McCune WJ, Knight JS

Current opinion in rheumatology 2016; (28(3)):218-27 doi:10.1097/BOR.0000000000000269.

Lupus-anticoagulant testing at NOAC trough levels.

Ratzinger F, Lang M, Belik S, et al.

Thrombosis and haemostasis 2016; (116(2)):235-40 doi:10.1160/TH16-02-0081.

Low level autoantibodies can be frequently detected in the general Australian population.

Deshpande P, Lucas M, Brunt S, et al.

Pathology 2016; (48(5)):483-90.

Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.

Yelnik CM, Urbanski G, Drumez E, et al.

Lupus 2017; (26(2)):163-169 doi:10.1177/0961203316657433.

EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.

Andreoli L, Bertsias GK, Agmon-Levin N, et al.

Annals of the rheumatic diseases 2017; (76(3)):476-485 doi:10.1136/annrheumdis-2016-209770.

[2016 review on catastrophic antiphospholipid syndrome].

Costedoat-Chalumeau N, Coutte L, Le Guern V, et al.

Presse medicale (Paris, France : 1983) 2016; (45(12 Pt 1)):1084-1092 doi:10.1016/j.lpm.2016.07.023.

Prevention of thrombosis in antiphospholipid syndrome.

Lim W

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):707-713 doi:10.1182/asheducation-2016.1.707.

Recent advances in understanding antiphospholipid syndrome.

Bertolaccini ML, Sanna G

F1000Research 2016; (5()):2908 doi:10.12688/f1000research.9717.1.

Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.

Saccone G, Berghella V, Maruotti GM, et al.

American journal of obstetrics and gynecology 2017; (216(5)):525.e1-525.e12 doi:10.1016/j.ajog.2017.01.026.

[Laboratory diagnosis of antiphospholipid syndrome: From criteria to practice].

Joste V, Dragon-Durey MA, Darnige L

La Revue de medecine interne 2018; (39(1)):34-41 doi:10.1016/j.revmed.2017.02.006.

Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Sciascia S, Amigo MC, Roccatello D, Khamashta M

Nature reviews. Rheumatology 2017; (13(9)):548-560 doi:10.1038/nrrheum.2017.124.

Thrombocytopenia in high-risk patients with antiphospholipid syndrome.

Pontara E, Banzato A, Bison E, et al.

Journal of thrombosis and haemostasis : JTH 2018; (16(3)):529-532 doi:10.1111/jth.13947.

Update on antiphospholipid antibody syndrome.

Lopes MRU, Danowski A, Funke A, et al.

Revista da Associacao Medica Brasileira (1992) 2017; (63(11)):994-999 doi:10.1590/1806-9282.63.11.994.

Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment.

Chighizola CB, Meroni PL

Current rheumatology reports 2018; (20(7)):44 doi:10.1007/s11926-018-0741-5.

McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Legault K, Schunemann H, Hillis C, et al.

Journal of thrombosis and haemostasis : JTH 2018; (16(8)):1656-1664 doi:10.1111/jth.14192.

Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome.

Yelnik CM, Lambert M, Drumez E, et al.

Lupus 2018; (27(10)):1679-1686 doi:10.1177/0961203318787032.

Antiphospholipid syndrome: An update on risk factors for pregnancy outcome.

De Carolis S, Tabacco S, Rizzo F, et al.

Autoimmunity reviews 2018; (17(10)):956-966 doi:10.1016/j.autrev.2018.03.018.

Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Zuo Y, Barbhaiya M, Erkan D

Current rheumatology reports 2018; (20(11)):66 doi:10.1007/s11926-018-0775-8.

Clinical profiles and risk assessment in patients with antiphospholipid antibodies.

Kato M, Hisada R, Atsumi T

Expert review of clinical immunology 2019; (15(1)):73-81 doi:10.1080/1744666X.2019.1543025.

Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.

Favaloro EJ, Mohammed S, Curnow J, Pasalic L

Pathology 2019; (51(3)):292-300 doi:10.1016/j.pathol.2018.11.008.

IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers.

Tonello M, Mattia E, Favaro M, et al.

Thrombosis research 2019; (177()):157-160 doi:10.1016/j.thromres.2019.03.006.

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, et al.

Annals of the rheumatic diseases 2019; (78(10)):1296-1304 doi:10.1136/annrheumdis-2019-215213.

Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies.

Tufano A, Di Minno MND, Guida A, et al.

Seminars in thrombosis and hemostasis 2019; (45(5)):468-477 doi:10.1055/s-0039-1692702.

CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission.

Pineton de Chambrun M, Larcher R, Pène F, et al.

Journal of autoimmunity 2019; (103()):102292 doi:10.1016/j.jaut.2019.06.003.

Managing antiphospholipid syndrome in pregnancy.

Schreiber K, Hunt BJ

Thrombosis research 2019; (181 Suppl 1()):S41-S46 doi:10.1016/S0049-3848(19)30366-4.

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.

Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al.

Annals of internal medicine 2019; (171(10)):685-694 doi:10.7326/M19-0291.

Antiphospholipid Antibody Syndrome and Infertility.

Rodrigues VO, Soligo AGES, Pannain GD

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2019; (41(10)):621-627 doi:10.1055/s-0039-1697982.

Genetics of Antiphospholipid Syndrome.

Ortiz-Fernández L, Sawalha AH

Current rheumatology reports 2019; (21(12)):65 doi:10.1007/s11926-019-0869-y.

Familial Clustering of Antiphospholipid Syndrome.

Saadia A, Khan SH, Khan MD

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019; (29(12)):1221-1224 doi:10.29271/jcpsp.2019.12.1221.

Epidemiology of Antiphospholipid Syndrome in Korea: a Nationwide Population-based Study.

Hwang JJ, Shin SH, Kim YJ, et al.

Journal of Korean medical science 2020; (35(5)):e35 doi:10.3346/jkms.2020.35.e35.

Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.

De Kesel PM, Devreese KMJ

Journal of thrombosis and haemostasis : JTH 2020; (18(8)):2003-2017 doi:10.1111/jth.14894.

The Issue of the Antiphospholipid Antibody Syndrome.

Oliveira DC, Correia A, Oliveira C

Journal of clinical medicine research 2020; (12(5)):286-292 doi:10.14740/jocmr4154.

Antiphospholipid syndrome and its role in pediatric cerebrovascular diseases: A literature review.

Sarecka-Hujar B, Kopyta I

World journal of clinical cases 2020; (8(10)):1806-1817 doi:10.12998/wjcc.v8.i10.1806.

Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis.

Tripodi A, Cohen H, Devreese KMJ

Journal of thrombosis and haemostasis : JTH 2020; (18(7)):1569-1575 doi:10.1111/jth.14846.

"APS pregnancy - The offspring".

Bitsadze V, Nalli C, Khizroeva J, et al.

Lupus 2020; (29(11)):1336-1345 doi:10.1177/0961203320947154.

Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.

Cohen H, Efthymiou M, Devreese KMJ

Journal of thrombosis and haemostasis : JTH 2021; (19(4)):892-908 doi:10.1111/jth.15217.

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.

Devreese KMJ, de Groot PG, de Laat B, et al.

Journal of thrombosis and haemostasis : JTH 2020; (18(11)):2828-2839 doi:10.1111/jth.15047.

Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy.

Lee EE, Jun JK, Lee EB

Journal of Korean medical science 2021; (36(4)):e24 doi:10.3346/jkms.2021.36.e24.

Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management.

Rosina S, Chighizola CB, Ravelli A, Cimaz R

Current rheumatology reports 2021; (23(2)):10 doi:10.1007/s11926-020-00976-7.

Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers.

Calcaterra I, Ambrosino P, Vitelli N, et al.

Biomedicines 2021; (9(2)) doi:10.3390/biomedicines9020122.

Value of second-trimester uterine artery pulsatility index in pregnancies with systemic lupus erythematosus and/or antiphospholipid syndrome.

Canto MJ, Ortiz-Santamaria V, Palau J, et al.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2022; (35(25)):6586-6592 doi:10.1080/14767058.2021.1918090.

Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines.

Pastori D, Menichelli D, Cammisotto V, Pignatelli P

Frontiers in cardiovascular medicine 2021; (8()):715878 doi:10.3389/fcvm.2021.715878.

Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study.

Evangelatos G, Kravvariti E, Konstantonis G, et al.

Rheumatology (Oxford, England) 2022; (61(8)):3408-3413 doi:10.1093/rheumatology/keab882.

Epidemiology of Antiphospholipid Syndrome in the General Population.

Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A

Current rheumatology reports 2022; (23(12)):85 doi:10.1007/s11926-021-01038-2.

An Update on Antiphospholipid Syndrome.

Xourgia E, Tektonidou MG

Current rheumatology reports 2022; (23(12)):84 doi:10.1007/s11926-021-01051-5.

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.

Drosos GC, Vedder D, Houben E, et al.

Annals of the rheumatic diseases 2022; (81(6)):768-779 doi:10.1136/annrheumdis-2021-221733.

Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis.

Tektonidou MG

Journal of autoimmunity 2022; (128()):102813 doi:10.1016/j.jaut.2022.102813.

Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre.

Barilaro G, Coloma-Bazan E, Chacur A, et al.

Autoimmunity reviews 2022; (21(12)):103208 doi:10.1016/j.autrev.2022.103208.

Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome.

Anunciación-Llunell A, Muñoz C, Roggenbuck D, et al.

International journal of molecular sciences 2022; (23(21)) doi:10.3390/ijms232112819.

Cutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients.

Dupré A, Morel N, Yelnik C, et al.

JAMA dermatology 2023; (159(1)):62-67 doi:10.1001/jamadermatol.2022.5221.

Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients.

Stammler R, Nguyen Y, Yelnik C, et al.

Journal of thrombosis and haemostasis : JTH 2023; (21(5)):1258-1265 doi:10.1016/j.jtha.2023.02.007.

Antiphospholipid Syndrome: State of the Art of Clinical Management.

Depietri L, Veropalumbo MR, Leone MC, Ghirarduzzi A

Cardiovascular drugs and therapy 2025; (39(2)):385-404 doi:10.1007/s10557-023-07496-3.

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

Barbhaiya M, Zuily S, Naden R, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(10)):1687-1702 doi:10.1002/art.42624.

Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?

Andreoli L, Regola F, Caproli A, et al.

Rheumatology (Oxford, England) 2024; (63(SI)):SI86-SI95 doi:10.1093/rheumatology/kead537.

Laboratory assessment of antiphospholipid syndrome: Laboratory data.

Kobylecki CJ, Vedel-Krogh S, Afzal S, Goetze JP

International journal of laboratory hematology 2024; (46(4)):714-721 doi:10.1111/ijlh.14273.

Testing for the lupus anticoagulant: the good, the bad, and the ugly.

Favaloro EJ, Pasalic L, Selby R

Research and practice in thrombosis and haemostasis 2024; (8(3)):102385 doi:10.1016/j.rpth.2024.102385.

Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?

Moyon Q, Mathian A, Papo M, et al.

Current rheumatology reports 2024; (26(7)):269-277 doi:10.1007/s11926-024-01148-7.

Obstetric antiphospholipid syndrome.

Soto-Peleteiro A, Gonzalez-Echavarri C, Ruiz-Irastorza G

Medicina clinica 2024; (163 Suppl 1()):S14-S21 doi:10.1016/j.medcli.2024.05.001.

Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes.

Meir K, Niznik S, Avnery O, et al.

The American journal of medicine 2025; (138(2)):269-276.e1 doi:10.1016/j.amjmed.2024.09.019.

Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.

Okunlola AO, Ajao TO, Sabi M, et al.

Cureus 2024; (16(9)):e69730 doi:10.7759/cureus.69730.

An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.

Devreese KMJ, Bertolaccini ML, Branch DW, et al.

Journal of thrombosis and haemostasis : JTH 2025; (23(2)):731-744 doi:10.1016/j.jtha.2024.10.022.

Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis.

De Pascali F, Filippova YA, Donadini MP, et al.

Thrombosis research 2025; (245()):109225 doi:10.1016/j.thromres.2024.109225.

Warfarin and heparin monitoring in antiphospholipid syndrome.

Mittal P, Sayar Z, Cohen H

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):192-199 doi:10.1182/hematology.2024000547.

Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease.

Salter BM, Crowther MA

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):214-221 doi:10.1182/hematology.2024000544.

Insights into the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary APS.

Zen M, Tonello M, Carta F, et al.

Rheumatology (Oxford, England) 2025; (64(7)):4325-4330 doi:10.1093/rheumatology/keae665.

Diagnosis and management of antiphospholipid syndrome.

Ahn Y, Hawkins C, Pearson E, Kubler P

Australian prescriber 2024; (47(6)):179-185 doi:10.18773/austprescr.2024.055.

Diagnostic, research, and real-life effect of the 2023 EULAR-ACR classification criteria for antiphospholipid syndrome.

Schreiber K, Aguilera S, Amengual O, et al.

The Lancet. Rheumatology 2025; (7(5)):e368-e376 doi:10.1016/S2665-9913(24)00396-5.

Distribution of HLA-DRB1 Alleles in Patients With Antiphospholipid Syndrome and Their Association With Antiphospholipid Antibodies Presence and Damage Indexes.

Haladyj E, Stypinska B, Matusiewicz A, et al.

Journal of immunology research 2025; (2025()):2827348 doi:10.1155/jimr/2827348.

Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.

Yang L, Guo R, Liu H, et al.

Frontiers in immunology 2025; (16()):1527554 doi:10.3389/fimmu.2025.1527554.

Unresolved issues in the diagnosis and management of thrombotic antiphospholipid syndrome.

Arachchillage DJ, Laffan M

Research and practice in thrombosis and haemostasis 2025; (9(2)):102724 doi:10.1016/j.rpth.2025.102724.

Perspective on Renal Involvement in Antiphospholipid Syndrome: Implications for Diagnosis, Pathogenesis, and Treatment.

Hoxha A, Del Prete D, Condonato I, et al.

Journal of clinical medicine 2025; (14(10)) doi:10.3390/jcm14103326.

Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR/EULAR antiphospholipid syndrome classification criteria.

Cobanoglu RK, Vega J, Burgos C, Erkan D

Seminars in arthritis and rheumatism 2025; (74()):152768 doi:10.1016/j.semarthrit.2025.152768.

Recurrent cardiac drug-eluting stent thrombosis due to antiphospholipid syndrome: a case report.

Lin KK, Wine YY, Aye ST

AME case reports 2025; (9()):160 doi:10.21037/acr-25-55.